PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013
17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice via decreasing MCP-1 mRNA Source: International Congress 2015 – Interstitial lung diseases II Year: 2015
Pre-clinical evaluation of a novel and selective PI3K δ/gamma inhibitor in pulmonary fibrosis Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Infliximab, an anti-tumor necrosis factor-α attenuates bleomycin-induced pulmonary fibrosis in rats Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013
Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013
Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016
Role of the TrkA receptor in experimental severe pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015
A transient receptor potential melastin-2 deficiency significantly worsens the fibrotic response to bleomycin in mice Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013
Effects of a highly selective CXCR3 antagonist in two murine models of lung inflammation Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014
Selective endothelin-A receptor blockade attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013
Olodaterol attenuates bleomycin induced lung fibrosis in mice Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016
Targeting the hedgehog/GLI pathway decreases bleomycin-induced lung fibrosis Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013
C21, a nonpeptide angiotensin II type 2 receptor agonist attenuates lung fibrosis and associated cardiac dysfunction Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015
The immunomodulatory effect of protein S in pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013
Comparison of expression of napsin A and surfactant protein D in bleomycin-induced pulmonary fibrosis mouse model Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013
CHI-91040, a novel inhaled p38α inhibitor, counteracts lung inflammation induced by IL-1β in the rat Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016
Late Breaking Abstract: Anti-fibrogenic effects of the endothelin-A receptor antagonist ambrisentan in a mouse pulmonary fibrosis model Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010
The attenuating effect of erythropoietin (EPO) on the expression of myeloperoxidase (MPO) in bleomycin-induced pulmonary fibrosis in rats Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013
Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice Source: Eur Respir J 2005; 25: 708-714 Year: 2005